​

Bicara Therapeutics (BCAX) Stock Forecast, Price Target & Predictions

OverviewOwnershipFinancialsChart

BCAX Stock Forecast

Bicara Therapeutics (BCAX) stock forecast, based on 4 Wall Street analysts, predicts a 12-month average price target of $40.00, with a high of $40.00 and a low of $40.00. This represents a 116.22% increase from the last price of $18.50.

BCAX Stock Rating

Bicara Therapeutics stock's rating consensus is Buy, based on 4 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 3 Buy (75.00%), 1 Hold (25.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 4 0 1 3 Strong Sell Sell Hold Buy Strong Buy

BCAX Price Target Upside V Benchmarks

TypeNameUpside
StockBicara Therapeutics116.22%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts--3
Avg Price Target--$32.00
Last Closing Price$18.50$18.50$18.50
Upside/Downside--72.97%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Dec, 25261--9
Nov, 25351--9
Oct, 25351--9
Sep, 25341--8
Aug, 25241--7
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 22, 2025Robert BurnsH.C. Wainwright$40.00$11.84237.84%116.22%
May 23, 2025Eva Fortea VerdejoWells Fargo$8.00$9.27-13.70%-56.76%
Mar 27, 2025Stifel Nicolaus$48.00$13.40258.21%159.46%
Oct 08, 2024Judah FrommerMorgan Stanley$35.00$24.4543.15%89.19%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 22, 2025H.C. WainwrightBuyBuyhold
Aug 18, 2025Piper SandlerOverweightinitialise
May 23, 2025Wells FargoUnderweightupgrade
Oct 08, 2024Cantor FitzgeraldOverweightinitialise
Oct 08, 2024Cowen & Co.Buyinitialise
Oct 08, 2024Morgan StanleyOverweightinitialise

Financial Forecast

EPS Forecast

Dec 24 Dec 25 Dec 26 Dec 27
Dec 24Dec 25Dec 26Dec 27
Reported$-0.40---
Avg Forecast$-2.59$-1.78$-2.61$-2.98
High Forecast$-1.38$-1.42$-2.54$-2.45
Low Forecast$-3.85$-2.50$-2.75$-3.35
Surprise %-84.56%---

Revenue Forecast

Dec 24 Dec 25 Dec 26 Dec 27
Dec 24Dec 25Dec 26Dec 27
Reported----
Avg Forecast----
High Forecast----
Low Forecast----
Surprise %----

Net Income Forecast

$-200M $-170M $-140M $-110M $-80M $-50M Dec 24 Dec 25 Dec 26 Dec 27
Dec 24Dec 25Dec 26Dec 27
Reported$-68.00M---
Avg Forecast$-135.35M$-92.49M$-140.06M$-150.11M
High Forecast$-71.43M$-73.50M$-131.47M$-126.81M
Low Forecast$-199.28M$-129.40M$-142.34M$-173.40M
Surprise %-49.77%---

BCAX Forecast FAQ

Is Bicara Therapeutics stock a buy?

Bicara Therapeutics stock has a consensus rating of Buy, based on 4 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 3 Buy, 1 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Bicara Therapeutics is a favorable investment for most analysts.

What is Bicara Therapeutics's price target?

Bicara Therapeutics's price target, set by 4 Wall Street analysts, averages $40 over the next 12 months. The price target range spans from $40 at the low end to $40 at the high end, suggesting a potential 116.22% change from the previous closing price of $18.5.

How does Bicara Therapeutics stock forecast compare to its benchmarks?

Bicara Therapeutics's stock forecast shows a 116.22% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and outperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Bicara Therapeutics over the past three months?

  • December 2025: 22.22% Strong Buy, 66.67% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • November 2025: 33.33% Strong Buy, 55.56% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.
  • October 2025: 33.33% Strong Buy, 55.56% Buy, 11.11% Hold, 0% Sell, 0% Strong Sell.

What is Bicara Therapeutics’s EPS forecast?

Bicara Therapeutics's average annual EPS forecast for its fiscal year ending in December 2025 is $-1.78, marking a 345.00% increase from the reported $-0.4 in 2024. Estimates for the following years are $-2.61 in 2026, and $-2.98 in 2027.

What is Bicara Therapeutics’s revenue forecast?

Bicara Therapeutics's average annual revenue forecast for its fiscal year ending in December 2025 is $0, reflecting a 0% decrease from the reported $0 in 2024. The forecast for 2026 is $0, and $0 for 2027.

What is Bicara Therapeutics’s net income forecast?

Bicara Therapeutics's net income forecast for the fiscal year ending in December 2025 stands at $-92.493M, representing an 36.03% increase from the reported $-67.995M in 2024. Projections indicate $-140M in 2026, and $-150M in 2027.